Type i diabetes therapy
AssigneeSt. Vincent's Institute of Medical Research
InventorsHelen E. Thomas, Thomas W. H. Kay, Balasubramanian Krishnamurthy, Gaurang Jhala
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel methods and therapies for treating, preventing or delaying the onset of type 1 diabetes. In one aspect, the invention provides a method of preventing, delaying the onset of, or delaying the progression of, type 1 diabetes (T1D) in an individual, the method comprising providing in the individual an anti-inflammatory compound; and a pancreatic autoantigen or a derivative or variant thereof; thereby preventing, delaying the onset of, or delaying the progression of, T1D in the individual.
Claims32
A method of preventing, delaying the onset of, or delaying the progression of, type 1 diabetes (T1D) in an individual having or at risk of having T1D, the method comprising providing in the individual:
- an anti-inflammatory compound;
- and
- a pancreatic autoantigen or a derivative or variant thereof;
- thereby preventing, delaying the onset of, or delaying the progression of, T1D in the individual.
3-4. (canceled)
(canceled)
8-10. (canceled)
(canceled)
(canceled)
16-20. (canceled)
23-24. (canceled)
26-27. (canceled)
(canceled)
(canceled)
35-39. (canceled)
A composition comprising an anti-inflammatory compound and a pancreatic autoantigen or a derivative or variant thereof.
A method for prolonging the production of endogenous insulin in an individual at risk of, or showing early symptoms of T1D, the method comprising providing in the individual:
- an anti-inflammatory compound;
- and
- proinsulin or a derivative or variant thereof;
- thereby prolonging the production of endogenous insulin in the individual.
44-53. (canceled)
Dependencies are inferred from the claim text.